Biocon Q3 net up 25%, licences drug to Pak firmBS Reporter / Bangalore January 18, 2007Bangalore-based biotech major Biocon today a reported 25% increase in net profit at Rs 55 crore for third quarter ended December 31, 2006 as against Rs 44 crore in Q3FY06.According to the release issued by the company, total income during the quarter grew by 22.88% at Rs 247 crore as compared to Rs 201 crore clocked in Q3FY06.The company's EBITDA has also gone up by 26.22% at Rs 77 crore against Rs 61 crore clocked in Q306.On sequential basis, net profit of the company was up 22.22% at Rs 55 crore as compared to Rs 45 crore in Q2FY07. Revenues marginally dipped by 1.2% at Rs 247 crore as against Rs 250 crore in Q2FY07.Kiran Mazumdar-Shaw, chairman & managing director, Biocon said: "Every business segment of the company has begun to deliver and capacity constrains been eased. We are confident that Biocon
